Impact of Intraoperative PTCD Catheter Retention Versus Removal on Postoperative Short-term Outcomes After Pancreaticoduodenectomy in Obstructive Jaundice

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-85
SponsorXu'an Wang

About this trial

Pancreaticoduodenectomy (PD) is a complex surgical procedure commonly performed for tumors of the pancreatic head and periampullary region. Many patients present with obstructive jaundice and undergo preoperative percutaneous transhepatic cholangial drainage (PTCD) to relieve biliary obstruction. However, there is currently no consensus on whether the PTCD catheter should be removed or retained during surgery.

This multicenter, prospective randomized controlled trial aims to compare two intraoperative strategies: removal versus retention of the PTCD catheter during PD. Participants will be randomly assigned to either group. The study will evaluate whether these different approaches influence postoperative outcomes, particularly major complications such as bile leak and severe postoperative morbidity within 90 days after surgery.

In addition to complications, the study will assess recovery after surgery, including return of gastrointestinal function, length of hospital stay, and quality of recovery, as well as laboratory indicators of liver function and inflammation.

The results of this study are expected to provide evidence to guide surgical decision-making regarding PTCD management during PD and to improve patient outcomes.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Age 18 to 85 years

Patients with pancreatic head or periampullary tumors scheduled for pancreaticoduodenectomy

Presence of obstructive jaundice and completion of preoperative

percutaneous transhepatic cholangial drainage (PTCD)

Disqualifiers

Presence of distant metastasis or locally unresectable disease

Severe cardiac, renal, or pulmonary dysfunction that contraindicates surgery

Uncontrolled infection

Pregnancy or breastfeeding

Trial design

Design model

Parallel

Treatments tested in this trial

  • PTCD Catheter Removal

    Procedure/Surgery

    The preoperative percutaneous transhepatic cholangial drainage (PTCD) catheter is removed intraoperatively during pancreaticoduodenectomy. Removal is performed after completion of the biliary-enteric anastomosis, followed by closure of the hepatic duct puncture site. No external biliary drainage is maintained postoperatively, and only standard abdominal drainage is used.

  • PTCD Catheter Retention

    Procedure/Surgery

    The preoperative percutaneous transhepatic cholangial drainage (PTCD) catheter is retained intraoperatively during pancreaticoduodenectomy. The catheter is used as a stent to support the biliary-enteric anastomosis and is maintained for postoperative external biliary drainage. Planned removal is performed approximately 4 weeks after surgery following confirmation of biliary patency by clamping trial and cholangiography.

Treatment groups

100 Participants
are divided into 2 treatment groups
Group A: PTCD Catheter Removal GroupExperimental treatment 1 intervention
Group B: PTCD Catheter Retention GroupExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Composite rate of major postoperative complications

Incidence of a composite endpoint defined as B/C-grade bile leak according to the International Study Group of Liver Surgery (ISGLS) criteria or Clavien-Dindo grade ≥ III complications occurring after pancreaticoduodenectomy.

Time frame
Up to 90 days

Secondary outcomes

1

B/C-grade bile leak

Incidence of B/C-grade bile leak defined according to ISGLS criteria.

Time frame
Up to 90 days
2

B/C-grade pancreatic fistula

Incidence of clinically relevant postoperative pancreatic fistula (grade B/C) defined by ISGPS criteria.

Time frame
Up to 90 days
3

Postoperative infections

Incidence of postoperative infections, including intra-abdominal infection, biliary infection, pulmonary infection, and wound infection.

Time frame
Up to 90 days
4

Time to gastrointestinal recovery

Time to first flatus and time to first oral intake after surgery.

Time frame
Up to 30 days

Other outcomes

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Xu'an Wang

Lead sponsor

Fudan University

Sponsor institution

This trial is not recruiting at the moment. You can still explore other options: